FDA’s DTC Coupon Study Triggers First Amendment Objections From PhRMA

FDA’s third attempt at studying the effects of coupons in direct-to-consumer print advertising triggers First Amendment concerns and raises the specter of regulatory restrictions based upon “potential deception,” according to the Pharmaceutical Research and Manufacturers of America.